两种重组蛋白疫苗候选物在恒河猴中对寨卡病毒感染的保护效果存在差异
研究在恒河猴中比较了两种寨卡病毒重组亚单位疫苗候选物(EDIII 与 E80)的免疫原性和保护效果。两者均诱导中和抗体反应,但仅 E80 免疫能抑制外周血和猴组织中的寨卡病毒感染,而 EDIII 可能通过抗体依赖性增强作用增加血中寨卡病毒 RNA。E80 免疫猴的病毒颗粒结合抗体反应比 EDIII 免疫猴更持久且更强。
要点
- E80 与 EDIII 在恒河猴中均诱导中和抗体,但仅 E80 抑制寨卡病毒感染。
- EDIII 免疫可能通过抗体依赖性增强导致血中寨卡病毒 RNA 增加。
- E80 免疫猴的病毒颗粒结合抗体反应更持久且更强,为保护相关标志。
核心结论
- E80 是优于 EDIII 的寨卡病毒疫苗候选物。
- 病毒颗粒结合中和抗体的强度、质量和持久性是保护的相关标志。
研究设计与样本
- 在恒河猴中比较先前构建的两种寨卡病毒重组亚单位疫苗候选物 EDIII 和 E80 的免疫原性与保护效果。
主要发现
- EDIII 和 E80 均诱导中和抗体反应。
- 仅 E80 免疫抑制外周血和猴组织中的寨卡病毒感染。
- EDIII 免疫可能通过抗体依赖性增强增加血中寨卡病毒 RNA。
- E80 免疫猴的病毒颗粒结合抗体反应比 EDIII 免疫猴更持久且更强。
临床怎么用
- E80 可作为优先开发的寨卡病毒疫苗候选物。
- 评估寨卡疫苗时需关注病毒颗粒结合中和抗体的强度、质量和持久性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Zika virus (ZIKV) infection has caused major public health problems recently. To develop subunit vaccines for ZIKV, we have previously constructed recombinant ZIKV envelope protein domain III (EDIII), and the entire ectodomain (E80, which comprises EDI, EDII and EDIII), as vaccine candidates and showed both of them being immunogenic and protective in murine models. In this follow-up study, we compared these vaccine candidates in non-human primates. Both of them elicited neutralizing antibody responses, but only E80 immunization inhibited ZIKV infection in both peripheral blood and monkey tissues, whereas EDIII increased blood ZIKV RNA through possibly antibody-dependent enhancement. Further investigations revealed that the virion-binding antibody response in E80 immunized monkeys persisted longer and stronger than in EDIII immunized monkeys. These results demonstrate that E80 is superior to EDIII as a vaccine candidate, and that the magnitude, quality and durability of virion-binding neutralizing antibodies are correlates of protection.
引用
- Yang R, Liu Q, Pang W, et al. Two immunogenic recombinant protein vaccine candidates showed disparate protective efficacy against Zika virus infection in rhesus macaques. Vaccine. 2021. PMID: 33451779. doi:10.1016/j.vaccine.2020.12.077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。